Abstract
Research QuestionThe effects of antinuclear antibodies (ANAs) on oocytes and embryos during IVF/ICSI procedures remain controversial. Do ANAs affect blastocyst aneuploidy rates during preimplantation genetic testing for aneuploidy (PGT-A) cycles? DesignWe conducted a retrospective cohort study of 259 patients who underwent PGT-A and immunological screening at our center between May 2018 and May 2023. Patients were divided into an ANAs-negative (ANAs-) group (213 cycles) and an ANAs-positive (ANAs+) group (46 cycles) based on the presence of ANAs, and embryo outcomes were compared. ResultsThere were significant differences between the ANAs- and ANAs+ groups in terms of male age (34 vs. 37 years, P=0.032), maternal age (33 vs. 35 years, P=0.046) and infertility duration (2 vs. 3 years, P=0.009), but there were no significant differences in the number of retrieved oocytes, metaphase II (MII) stage oocytes, available embryos, high-quality embryos, blastocysts biopsied, euploid blastocysts, MII stage oocyte rate, fertilization rate and high-quality embryo rate and euploidy rate. Multiple linear regression revealed that in infertile couples who underwent PGT-A treatment, only the maternal age was an independent factor influencing euploidy rates (regression coefficient of -0.009), whereas the presence of ANAs was not an independent factor influencing euploidy rates. ConclusionIn couples who underwent PGT-A treatment, the presence of ANAs did not affect the euploid rate, and this study did not observe any negative effects of ANAs on oocytes or embryos outcomes.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call